Short answer
Absci Corp (ABSI) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results covered the quarter ended June 30, 2026.
Absci Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results covered the quarter ended June 30, 2026
- Financial details and management commentary provided in Exhibit 99.1 press release
- Results announcement furnished under Item 2.02, making the release material investor information
Item 8.01 · Other Events
- Absci released an August 11, 2026 investor presentation with internal pipeline program updates
- Presentation provides investors current visibility into drug-development priorities and pipeline progress
- Exhibit 99.2 and company “News & Events” materials contain the substantive program details
Item EX-99.1 · Exhibit EX-99.1
- Positive interim Phase 1 ABS-201 data: favorable safety profile and estimated half-life of at least 65 days
- Pattern hair-loss interim proof-of-concept data expected second half 2026, with full readout targeted for early 2027
- $100 million underwritten offering included $40 million strategic investment from Eli Lilly, strengthening validation and funding
- Cash, cash equivalents, and marketable securities increased to $201.1 million, supporting operations into second half 2028
- Second-quarter net loss widened to $33.2 million from $30.6 million as R&D spending rose to $22.6 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Absci Corp 8-K filings
Get the next ABSI 8-K as it lands
Follow ABSI for push alerts, or ask the research agent what this filing means.